Morgan Stanley
ARAV

Morgan Stanley’s Aravive, Inc. Common Stock ARAV Stock Holding History

Morgan Stanley’s Portfolio ARAV Stock Details ARAV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-6,005
Closed -$742 – 8107
2023
Q4 		$742 Sell
6,005
-15,001
-71% -$2.05K ﹤0.01% 7241
2023
Q3 		$2.77K Sell
21,006
-62,999
-75% -$39.6K ﹤0.01% 7056
2023
Q2 		$106K Sell
84,005
-9,582
-10% -$15.5K ﹤0.01% 5930
2023
Q1 		$187K Buy
93,587
+14,496
+18% +$27.2K ﹤0.01% 5732
2022
Q4 		$104K Sell
79,091
-19,021
-19% -$24.3K ﹤0.01% 5956
2022
Q3 		$80K Sell
98,112
-5,999
-6% -$5.16K ﹤0.01% 6191
2022
Q2 		$103K Buy
104,111
+37,562
+56% +$49.6K ﹤0.01% 6265
2022
Q1 		$128K Sell
66,549
-1,716
-3% -$3.69K ﹤0.01% 6168
2021
Q4 		$150K Buy
68,265
+27,479
+67% +$91.4K ﹤0.01% 6214
2021
Q3 		$151K Sell
40,786
-143,385
-78% -$612K ﹤0.01% 6145
2021
Q2 		$1.1M Buy
184,171
+158,101
+606% +$836K ﹤0.01% 5024
2021
Q1 		$171K Sell
26,070
-6,911
-21% -$45.4K ﹤0.01% 5754
2020
Q4 		$186K Buy
32,981
+6,813
+26% +$37.4K ﹤0.01% 5632
2020
Q3 		$123K Sell
26,168
-27,414
-51% -$195K ﹤0.01% 5335
2020
Q2 		$623K Buy
53,582
+38,082
+246% +$452K ﹤0.01% 4490
2020
Q1 		$89K Sell
15,500
-4,754
-23% -$42.6K ﹤0.01% 5232
2019
Q4 		$277K Buy
20,254
+1,654
+9% +$14.6K ﹤0.01% 5262
2019
Q3 		$140K Buy
18,600
+7,913
+74% +$49.3K ﹤0.01% 5312
2019
Q2 		$64K Sell
10,687
-1,784
-14% -$11.1K ﹤0.01% 5507
2019
Q1 		$87K Sell
12,471
-2,835
-19% -$14.8K ﹤0.01% 5457
2018
Q4 		$54K Sell
15,306
-20,377
-57% -$117K ﹤0.01% 5741
2018
Q3 		$300K Sell
35,683
-3,227
-8% -$34K ﹤0.01% 5267
2018
Q2 		$472K Buy
38,910
+25,994
+201% +$268K ﹤0.01% 5148
2018
Q1 		$127K Sell
12,916
-156,179
-92% -$1.76M ﹤0.01% 5637
2017
Q4 		$2.23M Buy
169,095
+161,329
+2,077% +$2.08M ﹤0.01% 3940
2017
Q3 		$114K Buy
7,766
+1,673
+27% +$169K ﹤0.01% 5538
2017
Q2 		$638K Sell
6,093
-2,953
-33% -$317K ﹤0.01% 4649
2017
Q1 		$1.16M Sell
9,046
-6,574
-42% -$693K ﹤0.01% 4269
2016
Q4 		$1.4M Buy
15,620
+13,092
+518% +$992K ﹤0.01% 4209
2016
Q3 		$185K Buy
2,528
+1,539
+156% +$111K ﹤0.01% 5054
2016
Q2 		$65K Buy
989
+144
+17% +$8.19K ﹤0.01% 5436
2016
Q1 		$41K Buy
845
+52
+7% +$2.76K ﹤0.01% 5690
2015
Q4 		$59K Sell
793
-2,128
-73% -$143K ﹤0.01% 5645
2015
Q3 		$203K Sell
2,921
-6,599
-69% -$619K ﹤0.01% 5074
2015
Q2 		$870K Buy
9,520
+7,598
+395% +$770K ﹤0.01% 4312
2015
Q1 		$212K Sell
1,922
-483
-20% -$56.7K ﹤0.01% 5176
2014
Q4 		$324K Sell
2,405
-600
-20% -$70.2K ﹤0.01% 4967
2014
Q3 		$343K Sell
3,005
-13,418
-82% -$1.78M ﹤0.01% 4822
2014
Q2 		$2.76M Buy
+16,423
New +$2.83M ﹤0.01% 3229

Other funds holding ARAV

Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.87B AUM 24.64% 1-Year Est. Return

Morgan Stanley's ARAV Position: Q1 2024 in Review

Morgan Stanley sold out of Aravive, Inc. Common Stock (ARAV) in Q1 2024, closing a stake of 6,005 shares — an estimated $742 sold.

Morgan Stanley first reported a position in ARAV in Q2 2014 and held it in 39 quarters. The position peaked at $2.76M in Q2 2014. 3 funds tracked by Wall St. Rank hold ARAV as of Q1 2024.

  • Morgan Stanley reported no remaining Aravive, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Morgan Stanley sold 6,005 Aravive, Inc. Common Stock shares in Q1 2024, an estimated $742.
  • Morgan Stanley first reported a position in Aravive, Inc. Common Stock in Q2 2014 and held it in 39 quarters.
  • Morgan Stanley's Aravive, Inc. Common Stock position peaked at $2.76M in Q2 2014.
  • 3 funds tracked by Wall St. Rank held Aravive, Inc. Common Stock as of Q1 2024.

Based on Morgan Stanley's 13F filing for Q1 2024, filed 15 May 2024.